Samantha Du, Zai Lab CEO
August 10, 2022 06:35 AM EDTUpdated 04:34 PM
R&D

Up­dat­ed: Any­one still look­ing for a CD47? Zai Lab shelves PhI pro­gram af­ter re­view­ing 'com­pet­i­tive land­scape'

Amber Tong

Over the past few years, the promise of block­ing CD47 — a “don’t eat me” sig­nal co-opt­ed by can­cer cells — has sent drug­mak­ers big and small …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Stephen Squin­to's JPM life sci­ences team is rais­ing a new fund for lat­er-stage com­pa­nies

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times